TRPV1 nociceptors are required to optimize antigen-specific primary antibody responses to novel antigens
Aisling Tynan(Northwell Health), Kevin J. Tracey(Northwell Health), Michael Brines(Northwell Health), Téa Tsaava(Feinstein Institute for Medical Research), Carlos E. Bravo‐Iñiguez(Northwell Health), Manojkumar Gunasekaran(Northwell Health), Sangeeta S. Chavan(Feinstein Institute for Medical Research)
Cited by 13
Related Papers
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
|Proceedings of the National Academy of Sciences|2000|1.4k
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
|Molecular Medicine|2002|1k
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
|Proceedings of the National Academy of Sciences|2001|1k
Sepsis: a roadmap for future research
|The Lancet Infectious Diseases|2015|1k